Makoto Asano

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

Yasuhiro Funahashi, Kiyoshi Okamoto, Yusuke Adachi et al. · Cancer Science · 2014 · 275 citations · Full text

Breast Oncology, Biological Microenvironments, Pathology +19

Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.

Makoto Asano, Ayako Yukita, T Matsumoto et al. · PubMed · 1995 · 260 citations

Immunology, Pathology, Immunotherapy +17

Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients

Shinichi Kondo, Makoto Asano, Katsuhiko Matsuo et al. · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · 1994 · 195 citations

Angiogenesis, Medicine, Immunology +12

Significance of Vascular Endothelial Growth Factor/Vascular Permeability Factor for Solid Tumor Growth, and Its Inhibition by the Antibody

Shinichi Kondo, Makoto Asano, Hideo Suzuki · Biochemical and Biophysical Research Communications · 1993 · 171 citations

Angiogenesis, Immunology, Pathology +9

Mutagenesis of human granulocyte colony stimulating factor

Tetsurō Kuga, Yoshinori Komatsu, Motoo Yamasaki et al. · Biochemical and Biophysical Research Communications · 1989 · 105 citations

Granulocyte, Pathogenesis, Hematology +6